Ablynx(比利時(shí))

Ablynx

比利時(shí)Ablynxwww.ablynx.comAblynx(歐洲證券交易所:ABLX)是一家生物制藥公司，致力于研究和開(kāi)發(fā)納米抗體，納米抗體是一類新型治療性蛋白，含有自然產(chǎn)生的單域抗體的獨(dú)特結(jié)構(gòu)和功能特性，用于治療一系列嚴(yán)重的，危害生命的人類疾病，包括炎性疾病，血栓，腫瘤和肺部疾病。今天，公司擁有多達(dá)25個(gè)新產(chǎn)品項(xiàng)目，其中7個(gè)納米抗體已應(yīng)用于臨床開(kāi)發(fā)。Ablynx正與某些大型醫(yī)藥公司進(jìn)行成果卓越的 研究合作.其中包括勃林格殷格翰,默克雪蘭諾,諾華和輝瑞。公司總部設(shè)在比利時(shí)根特，現(xiàn)有員工280多名。AblynxisabiopharmaceuticalcompanyengagedinthediscoveryanddevelopmentofNanobodies®,anovelclassoftherapeuticproteinsbasedonsingle-domainantibodyfragments,forarangeofseriousandlife-threateninghumandiseases,includinginflammation,haematology,oncologyandpulmonarydisease.Today,theCompanyhasover25projectsinthepipelineandsevenNanobodiesinclinicaldevelopment.Todate,AblynxhasgeneratedNanobodiesagainstmorethan235differentdiseasetargetsandhascharacterisedpotentantagonistsinvitroagainst38differenttargets.TheCompanyanditscollaboratorshaveobtainedpositiveinvivoefficacydatafromanimalstudiesineightmajortherapeuticprogr